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The development and progression of renal cysts appears to
be driven by reduced cellular calcium and increased cyclic
adenosine monophosphate (cAMP) from G-protein-coupled
receptors. To test whether treatment with a calcimimetic that
stimulates the G-protein-coupled calcium-sensing receptor
might normalize cystic epithelial cell intracellular calcium and
cAMP, thereby inhibiting cyst progression, we used pcy mice.
These animals develop cysts principally in the collecting duct,
as do humans with nephronophthisis (NPHP). We
administered the calcimimetic R-568 mixed in their food at
early or late stages in the pathogenesis of cyst formation.
The treatment reduced cyst enlargement, and the early
treatment inhibited development of renal fibrosis. Although
the effect of later treatment was more modest, both stages of
the disease responded positively to treatment. Additionally,
R-568 decreased total kidney cAMP in the pcy mice and,
in vitro, decreased cAMP levels and cell proliferation, while
increasing intracellular calcium in immortalized human
autosomal recessive polycystic kidney disease renal epithelial
cells. The latter two effects were unique to R-568 and not
replicated by raising extracellular calcium. Thus, treating pcy
mice with R-568 was effective in reducing cyst progression in
this rodent model of NPHP. Direct studies will be needed to
determine whether these results can be applied to the
human disease.
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Cystic kidney diseases due to genetic disorders are a leading
cause of kidney failure and death in children and adults. Two
childhood forms of renal cystic disease, autosomal recessive
polycystic kidney disease (ARPKD) and nephronophthisis
(NPHP), are characterized by collecting-duct cysts.1,2 Fibro-
cystin/polyductin, the protein encoded by the PKHD1 gene
mutated in ARPKD, and nephrocystin 3, from the NPHP3
gene, are localized to primary cilia.3 These cystic conditions
are associated with abnormalities in cilia structure or
function, altered regulation of cellular cyclic adenosine
monophosphate (cAMP) and intracellular calcium, and
increased epithelial cell proliferation and apoptosis.4 Thus,
interventions that reverse ciliary dysfunction, alter prolifera-
tion, or reverse the alterations in intracellular calcium/cAMP
may impact the progression of the disease.
Calcium is regulated by several hormones, including
parathyroid hormone (PTH) and calcitriol, acting on bone,
kidney, and the intestine.5 Extracellular calcium influences
intracellular actions through its binding to the CaSR, a
G-protein-linked receptor.6 Activation of the CaSR increases
intracellular calcium and decreases cAMP generation,7 effects
that would oppose the abnormalities in PKD. In the
collecting duct, the CaSR is located apically and appears to
sense increased luminal calcium and decreases arginine
vasopressin-dependent aquaporin-2 expression, perhaps to
dilute the urine and prevent hypercalciuria.8 Type I agonists
are inorganic polyvalent cations (for example, calcium and
magnesium) and activate the CaSR, without the need for
other agonists. In contrast, type II agonists, or calcimimetics,
are positive allosteric modulators of the CaSR. The first
generation type II CaSR agonist, R-568, was manufactured by
NPS (Oread Labs, Lawrence, KS), and the second generation
of calcimimetic, Cinacalcet, was developed by Amgen
(Amgen Thousand Oaks, CA) and is approved by the FDA
for use in the treatment of secondary hyperparathyroidism in
patients on dialysis. The primary difference between R-568
and Cinacalcet are the P450 drug interactions.9 We have
previously demonstrated that treatment with R-568 inhibited
cyst growth in the Cy/þ model of cystic kidney disease.
Kidney size, cyst volume density, fibrosis, and renal function
were all improved between 34 and 38 weeks of age, a time
when there is cyst growth of all tubular segments.10 In the
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present study, we determined the effect of R-568 on an
orthologous model of NPHP, the pcy mice, with cyst
formation derived principally from the collecting duct. The
results demonstrate that R-568 is effective in the prevention
of renal cystic disease progression in this animal model.
RESULTS
The effect of R-568 on the prevention of cystic disease in pcy
mice
NPHP (pcy) mice and normal CD1 mice were treated with
control or R-568 for 11 weeks, starting from 4 weeks of age.
There was no significant gender dimorphism in the cystic
disease progression in the pcy mouse model; therefore, male
and female data were combined. The observed changes in
serum biochemistries are shown in Table 1. There were
significant elevations in serum blood urea nitrogen, PTH,
phosphorus, and calcium in pcy mice compared with CD1
control mice (Table 1). R-568 treatment, compared with no
R-568, lowered serum PTH and blood urea nitrogen in pcy
mice but had no significant effect in CD1 mice. However,
there was no difference in serum calcium and phosphorus
concentration in R-568-treated animals (CD1 or pcy mice)
compared with non-treated animals.
The effect of R-568 on the kidneys is shown in Table 1 and
Figure 1. The pcy mice had significant renal pathology, with
enlarged kidneys, increased weight of kidneys, and fibrocystic
histopathology. R-568 treatment prevented much of the renal
histopathology in the early stage in NPHP in the pcy mouse.
For example, R-568 significantly decreased the total kidney
weight (0.66±0.21 versus 0.93±0.21 g, Po0.05) in pcy mice
but had no effect in CD1 mice. R-568 also reduced the
KW%BW in pcy mice (3.3±0.8 versus 4.8±1.1, Table 1,
Po0.05). There was also a significant reduction in cystic
change and fibrosis with R-568 treatment. R-568 significantly
decreased cyst volume density (%) in pcy mice (Table 1 and
Figure 1, Po0.05) and cyst volume (0.20±0.11 with R-568
versus 0.38±0.16ml without R-568, Po0.05, Table 1).
Furthermore, R-568 treatment reduced renal fibrosis
(Table 1). These results demonstrate the efficacy of R-568
treatment in slowing early-stage renal disease in this animal
model of NPHP.
The effect of R-568 on late-stage NPHP in pcy mice
As shown in Table 2, all three treatment groups (R-568,
Ca2þ , and R-568þCa2þ ) reduced serum PTH levels
compared with control (Po0.05), with no difference between
the three treatment groups. Calcium (with or without R-568)
significantly decreased serum phosphorus and increased
calcium levels versus control and R-568 alone. In contrast,
R-568 alone decreased serum calcium (Table 2). None of the
treatments significantly reduced blood urea nitrogen levels,
but there was a trend in reduction in the R-568-treated
group.
Among the three treatment groups, only R-568 alone
reduced total kidney weight (R-568: 0.75±0.15 versus
control: 0.94±0.30 g, Po0.05; Table 2 and Figure 2), whereas
the addition of calcium negated the effects of R-568.
Table 1 | Effect of R-568 on the early-stage renal disease in pcy and normal CD1 mice
pcy CD1
Treatment group (4–15 weeks) Control (n=20) R-568 (n=20) Control (n=22) R-568 (n=24)
BUN (mg/dl) 29.9±10.5* 24.8±3.0*# 20.7±3.2 19.7±2.7
PTH* (pg/ml) 201±136* 88±62*# 48±23 26±11
Phosphate (mg/dl) 9.9±2.1* 10.7±2.2* 6.4±1.3 7.0±1.4
Calcium (mg/dl) 8.8±1.2* 8.2±1.3* 5.9±0.7 6.7±1.2#
BW (g) 19.8±2.4* 19.9±1.9* 40.0±8.9 41.8±7.2
KW (g) 0.93±0.21* 0.66±0.21# 0.65±0.15 0.58±0.16
KW%BW 4.8±1.1* 3.3±0.8*# 1.6±0.2 1.4±0.2
Cyst vol density (%) 40.0±9.1 27.7±10#
Cyst vol (ml) 0.40±0.16 0.21±0.12#
Fibrosis score 4.0±0.0 3.0±0.3#
Abbreviations: BUN, blood urea nitrogen; BW, body weight; KW, kidney weight; PTH, parathyroid hormone.
KW%BW is KW as a percent of the total BW; cyst vol density is the cyst volume (assuming 1 g/cc of cyst) expressed as a percent of the total BW; cyst vol is the cyst volume in
cubic centimeters (cc) determined from the cyst volume density KW; and fibrosis score is based on a qualitative, 1+ to 4+ scale.
Data presented as mean±s.d.
*Po0.05, pcy versus CD1 mice, with or without R-568; #Po0.05, R-568 versus control, pcy, or CD1 mice.
Control R-568 treated
Figure 1 |Renal histopathology in pcy mice treated with R-568
from 5 to 15 weeks of age. At 15 weeks of age, pcy kidney
demonstrates diffuse cystic change and near-maximal cystic
enlargement (left panel). Treatment with 0.05% R-568 causes a
significant delay in the development of cystic pathology (right
panel). Scale bar¼ 1mm.
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Although there was a trend toward decreased cyst volume
density and cyst volume (Table 2 and Figure 2) in R-568-
treated animals, this change did not reach significance. Both
R-568- and R-568þ Ca2þ -treated animals demonstrated a
reduction in fibrosis, but only the R-568þ Ca2þ reached
significance (Table 2). These results demonstrate that R-568
treatment slowed the renal enlargement in the late stage of
NPHP.
Expression of CaSR in epithelial lining of the renal cyst in pcy
animals
The CaSR is described in the literature as being present in
proximal tubules, distal tubules, and the collecting ducts.11
However, its expression in cyst epithelium is unknown. To
confirm that the CaSR is expressed in cystic epithelium, we
performed in situ hybridization in kidney sections from
35-week pcy mice. The results demonstrate that the CaSR was
expressed in the medullary proximal and distal tubules,
as expected, and in the epithelial cells lining the renal cysts
(Figure 3). This suggests that the observed effect of R-568 on
renal cystic disease may be, at least in part, related to direct
activation of CaSR in the cysts.
The effect of R-568 on cAMP and proliferation
To determine the mechanism of the beneficial effects of R-568
on cystic kidney disease, we examined three potential
mechanisms—reduction in cAMP, increase in intracellular
calcium, and reduction in cell proliferation. Treatment of
R-568, Ca2þ , or R-568þ Ca2þ all significantly decreased
total kidney cAMP in pcy mice (Figure 4). These treatments
also decreased cAMP content in kidney when normalized by
kidney weight but only Ca2þ alone (57.4±6.8 versus
100.5±16.3 pmol/mg tissue, Po0.05) or R-568þ Ca2þ
(69.9±6.5 versus 100.5±16.3 pmol/mg tissue, Po0.05)
reached statistical difference. R-568 also decreased cAMP
(84.3±7.9 versus 100.5±16.3 pmol/mg tissue, P¼ 0.2), but
this was not statistically different from control. As all three of
these treatments also lowered PTH, we then examined the
direct effects of R-568 in vitro. As there is no NPHP renal
epithelial cell line available, we used human renal epithelial
cells isolated from a cystic (ARPKD) kidney and immorta-
lized as an in vitro cell model for childhood cystic kidney
disease. Our results demonstrated that R-568 lowered cAMP
secretion (Figure 5a) and cellular cAMP (Figure 5b), whereas
PTH increased cAMP, as has been previously reported in
Table 2 | Effect of R-568 on the late-stage renal disease in pcy mice
Treatment group (20–35 weeks) Control (n=22) R-568 (n=18) R-568+Ca2+ (n=19) Ca2+ (n=14)
BUN (mg/dl) 60.8±24.3 55.8±19.2 57.3±16.7 71.2±30.4
PTH (pg/ml) 320±235 94±97* 56±25* 75±48*
Phosphate (mg/dl) 8.6±1.9 8.7±1.5 6.8±2.0*# 5.9±2.4*#
Calcium (mg/dl) 8.6±0.3 7.4±0.3* 8.7±0.4# 9.7±0.4*#$
BW (g) 18.1±3.0 17.8±2.0 18.2±3.0 17.7±3.1
KW (g) 0.94±0.30 0.75±0.15* 1.01±0.34# 1.05±0.34#
KW%BW 5.1±1.0 4.2±0.7* 5.5±1.4# 5.9±1.1*#
Cyst vol density (%) 32.2±7.3 28.9±7.5 32.4±7.2 35.8±5.9
Cyst vol (ml) 0.31±0.15 0.26±0.17 0.32±0.14 0.39±0.15
Fibrosis score 4.7±0.5 4.3±0.4 4.1±0.4* 4.9±0.1#
Abbreviations: BUN, blood urea nitrogen; BW, body weight; KW, kidney weight; PTH, parathyroid hormone.
KW%BW is KW as a percent of the total BW; cyst vol density is the cyst volume (assuming 1 g/cc of cyst) expressed as a percent of the total BW; cyst vol is the cyst volume in
cubic centimeters (cc) determined from the cyst volume density KW; fibrosis score is based on a qualitative, 1+ to 4+ scale.
Data presented as mean±s.d.
*Po0.05 compared with control; #Po0.05 compared with R-568; and $Po0.05 compared with R-568+Ca2+.
Control R-568 R-568+Ca2+ Ca2+
Figure 2 |Renal histopathology in pcy mice treated with R-568 or calcium gluconate from 20 to 35 weeks. Pcy mice were treated with
0.05% R-568 with or without 2% calcium from 20 to 35 weeks of age. The renal cystic changes at 35 weeks are also associated with
increased fibrosis in control untreated animals (left panel). The treatment with R-568 alone was associated with a significant reduction in
kidney weight and a slight, but not significant, decrease in cystic pathology. However, treatment with Ca2þ gluconate (with or without R-
568) had no effect on pathology compared to the R-568 alone. Scale bar¼ 1mm.
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cultured bone and kidney epithelial cells.12,13 Thus, R-568, or
lowering PTH, had similar effects in vivo and in vitro, and
cannot fully explain the effects of R-568. We also examined
the effect of R-568 on intracellular calcium levels and found
R-568 increased intracellular calcium in immortalized human
ARPKD renal epithelial cells (Figure 5c). Given the changes
in cyst volume density that we observed, we next examined
cell proliferation in vitro to determine the direct effects of
R-568 on cystic epithelial cells. The results demonstrated that
R-568 dose dependently decreased cellular proliferation of
immortalized ARPKD renal epithelial cells, whereas calcium
had no effect (Figure 6). These results suggest that the
protective effects of R-568 may be due to multiple
mechanisms: reduction of cAMP, decreased proliferation,
and increased intracellular calcium, with the latter two
mechanisms differentiating R-568 from other PTH-lowering
therapies.
DISCUSSION
In the present study, we evaluated an animal model of cystic
kidney disease, the pcy model of human NPHP3, and
demonstrated that the calcimimetic R-568 was an effective
therapy. R-568 treatment significantly decreased kidney
weight, cyst volume, cyst volume density, and fibrosis when
given from 4 to 15 weeks, and thus prevented the disease
progression. This effect was further evident by the reduction
in blood urea nitrogen in the treated animals. In later stages
of disease in the pcy mouse, R-568 treatment significantly
decreased kidney weight, with a trend toward reduction in
cyst growth and fibrosis at 35 weeks. We also observed a
significant decrease in serum calcium in the late-stage-treated
mice. The low calcium may have confounded effects on cyst
growth, as the phosphodiesterase responsible for metaboliz-
ing vasopressin 2 receptor-generated cAMP is calcium
sensitive.4 Thus, it is possible that the failure of R-568 to
reduce cyst volume and fibrosis at later-stage pcy mice,
despite the statistically reduced kidney enlargement, may be
due to hypocalcemia offsetting the beneficial effects on
intracellular calcium and cAMP. However, it is more likely
due to differences in the pathogenesis of cyst growth at later
stages compared with earlier stages.
We then explored the mechanisms involved in the R-568
amelioration of cystic kidney disease. R-568 decreased total
kidney cAMP in pcy mice and inhibited cAMP, decreased
cellular proliferation, and increased intracellular calcium in
immortalized human ARPKD renal epithelial cells, suggest-
ing the beneficial effect of R-568 on kidney is via both a
reduction in cAMP and proliferation and an increase in
intracellular calcium, with the latter two unique to R-568
compared with calcium alone. Our studies also support that
a b c
AS probe AS probe S probe
Figure 3 | Expression of CaSR in epithelial lining of the renal cyst in pcy mice. To confirm the localization of the CaSR in cyst epithelial
cells, in situ hybridization was performed on the paraffin sections of the kidneys from 35-week pcy mice. The results demonstrate that
the CaSR was in the epithelial cells lining the renal cysts in pcy mice (a, b; arrow indicates CaSR expression). For negative controls, serial
sections were processed using sense probe (c). This suggests that the observed effect of R-568 on renal cystic disease may be directly
related to activation of CaSR in the cysts. Scale bar¼ 1mm (a) and 100mm (b, c). AS, antisense; S, sense.
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Figure 4 | The effect of R-568 on kidney cyclic adenosine
monophosphate (cAMP) content in pcy mice. Pcy mice were
treated with or without 0.05% R-568, 2% calcium gluconate
(Ca2þ ), or R-568 with Ca2þ from 20 to 35 weeks. The cAMP
content was determined and expressed as total kidney cAMP
content as well as normalized by kidney weight. The results
demonstrated that both R-568 and calcium or the combination of
R-568 and calcium significantly decreased total cAMP content in
pcy mice. *Po0.05, all treatments versus control.
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the mechanism by which R-568 reduces cAMP is through a
direct effect, in addition to a likely indirect effect by
decreasing PTH. Our in situ hybridization studies confirm
that the CaSR is located on cyst epithelium, providing
support of a direct role of R-568. Thus, R-568 may be able to
‘bypass’ the cilia abnormalities to correct defective down-
stream cell-signaling changes. These studies indicate that
R-568 is a potentially useful therapy for inhibition of renal
cyst growth, progression, and fibrosis in this animal model of
NPHP3 and complement our findings in the Cy/þ model of
cystic kidney disease where R-568 prevented late-stage cyst
growth and fibrosis.10
The finding that R-568 reduces cyst development, growth,
and/or fibrosis in both the pcy and Cy/þ animal models
suggests a commonality across the diseases. When activated
by increases in extracellular ionized calcium, or by the
allosteric activator R-568, the CaSR acts through the Gq
protein to activate phospholipase C-protein kinase C
signaling. This, in turn, leads to increased intracellular
calcium and, through the Gi protein, inhibition of cAMP
generation.14 This would reverse abnormalities that are
thought important in the pathogenesis of cyst formation.15,16
Our current study demonstrated that R-568 decreased total
kidney cAMP content in pcy mice, suggesting that the
beneficial effect on kidney of R-568 may be associated with a
reduction in cAMP. Also supporting this mechanism is that
lowering cAMP by the therapeutic use of vasopressin 2
receptor antagonists inhibits the development and progres-
sion of the renal cystic disease in animal models orthologous
to human autosomal dominant polycystic kidney disease
(Pkd2/WS25 mice), ARPKD (PCK rats), and NPHP (pcy
mice).17,18 In contrast, use of calcium-channel blockers,
which decreases intracellular calcium, accelerates PKD
progression.19 Nephrocystin 3, the protein defect resulting
from mutations in the NPHP3 gene, is localized to primary
cilia.3 The renal cilia are required for the physical and
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Figure 5 | The effect of R-568 on cyclic adenosine monophosphate (cAMP) content and intracellular calcium in immortalized human
autosomal recessive polycystic kidney disease (ARPKD) renal epithelial cells. Human ARPKD-immortalized renal epithelial cells were
treated with vehicle (control), R-568 (30 and 50 mmol/l), or parathyroid hormone (PTH; 10 nmol/l) for 24 h. cAMP in conditioned media and
cell lysate was determined using an immunoassay kit and normalized by total cellular protein. The results (a) demonstrated that R-568
reduced cAMP secretion in a dose-dependent manner, whereas PTH increased cAMP secretion in human ARPKD-immortalized renal
epithelial cells. Similarly, R-568 also inhibited cellular cAMP production, and PTH increased cellular cAMP in renal epithelial cells (b). Human
ARPKD-immortalized renal epithelial cells were treated with or without R-568 for 1 h and intracellular calcium examined using fura 4-AM by
confocal microscopy and quantified using Metamorph software. The results demonstrated that R-568 increased intracellular calcium in renal
epithelial cells (c). *Po0.05, versus control; #Po0.05, R-568 (50 mmol/l) versus R-568 (30 mmol/l); and $Po0.05, PTH versus other groups.
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chemical stimulation of intracellular calcium.20,21 and thus,
when genetically altered, lead to decreased intracellular
calcium and increased cAMP. However, the differences that
we observed between R-568 and calcium treatment, despite
similar effects on cAMP, indicate that changes in cAMP
cannot completely explain the beneficial effects of R-568.
Other abnormalities common to cystic diseases are defects
in planar cell polarity, increased rates of proliferation and
apoptosis, expression of a secretory phenotype, and remodel-
ing of the extracellular matrix.4 It is not clear whether these
abnormalities are directly related to changes in intracellular
calcium and cAMP or occur through other signaling
pathways. Our finding that R-568 directly reduced prolifera-
tion in vitro suggests an alternative or additional mechanism
by which R-568 may reduce cyst growth. Activation of the
CaSR is also known to reduce cell proliferation in
parathyroid cells,22 keratinocytes,23 colonic epithelium,24
and cancer cells.25,26 In addition, activation of the CaSR also
appears to affect terminal differentiation in these cells and
perhaps can explain the reduced fibrosis we observed. The
cell signaling pathways involved are diverse in these cell types.
However, Wnt signaling is a possibility, as the gene defect in
NHPH type II, inversion, is known to lead to alterations in
Wnt signaling.27 Another study demonstrated that mice
lacking the jouberin protein develop NHPH due to a decrease
in Wnt signaling and nuclear b-catenin accumulation.28
Clearly, more research is required to fully elucidate the role of
this signaling pathway in cystic epithelium.
It is important to note that Wang et al.29 did not find an
effect of R-568 on the PCK rat and PKD2/ws25 mouse using
0.05 and 0.1% R-568 mixed in food (B25 or 50mg/kg). They
treated PCK rats from 3 to 10 weeks and PKD2/ws25 mice
from 3 to 16 weeks. In these studies, they did not find a
reduction in cyst volume or kidney size in either model.
However, they did find a reduction in fibrosis in R-568-
treated PCK rats. This implies that different cell signaling
may be involved in fibrosis and cyst growth. In some series,
cyst growth in the PCK rat is greater at later stages of
disease,30 and thus it is also possible that the time points
examined may have been too early to observe an alteration in
cyst growth. More studies are required to understand the
differences observed in different animal models of cystic
disease.29
In conclusion, treatment of pcy mice, an orthologous
animal model of the cystic disease NPHP, with R-568
inhibited progression of cyst growth and renal fibrosis.
R-568 was less effective in later-stage NPHP but did
significantly reduce kidney weight. Taken together, these
results offer hope that calcimimetics may be a potential new
therapy for these devastating childhood diseases, although
the risk and benefits will need to be determined in a clinical
trial to ensure that hypocalcemia is not treatment limiting.
MATERIALS AND METHODS
Animal models and study design
The pcy mouse is a model of NPHP that is caused by a missense
mutation in NPHP3, the gene mutated in adolescent NPHP.31 The
pcy mouse develops renal cysts beginning at 5 weeks and then
plateaus between 15 and 20 weeks of age. Thereafter, the cysts
enlarge, culminating in severe azotemia at 35–40 weeks.17 Therefore,
we evaluated two different treatment periods: a preventive stage
where animals were treated from 4 to 15 weeks and a treatment
phase where animals were treated from 20 to 35 weeks. For the
prevention study, male and female pcy or wild-type CD1 mice were
provided with the following treatment diets: (1) control diet:
LabDiet no. 5002, diet without any additive (contains 0.862%
Ca2þand 0.62% P); (2) R568 diet: LabDiet (TestDiet, Richmond,
IN) no. 5002, diet with 0.05% R-568 (to deliver a dosage of
B50mg/kg/day). For the later-stage pcy mouse study, where there is
established secondary hyperparathyroidism, two additional treat-
ment arms were added to differentiate direct effects of R-568 from
that of calcium, which also lower PTH: (3) R-568þCa2þ : Pcy mice
fed the same diet as group 2, with the addition of 2% calcium
gluconate to the drinking water (R-568þCa2þ ) and (4) Ca2þ : Pcy
mice fed same diet as group 1, with the addition of 2% calcium
gluconate to the drinking water (Ca2þ ). We only utilized these latter
two treatments in the older animals, as we anticipated much greater
reductions in PTH at this stage of CKD.
The pcy mice were provided food and water, and maintained on
a 12 h/12 h, dark/light cycle. At termination, rodents were weighed,
anesthetized with sodium pentobarbital 100mg/kg given intraper-
itoneally, and blood collected via an intracardiac extraction. A
laparotomy was performed and the kidneys flushed with saline. The
left kidney was weighed and frozen, whereas the right kidney was
weighed and transverse sections fixed in 4% paraformaldehyde in
0.1mol/l phosphate buffer for processing for paraffin embedment.
Studies were approved by the Indiana University Institutional
Animal Care and Use Committee.
Plasma biochemistries
Sera were assayed for urea nitrogen (Sigma Urea Assay kit no. 640,
Sigma-Aldrich, St Louis, MO), intact PTH (ELISA kit from ALPCO
Diagnostics, Salem, NH), and calcium and phosphate concentra-
tions (Pointe Scientific, Canton, MI).
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Figure 6 | The effect of R-568 on cellular proliferation in renal
epithelial cells. Immortalized human autosomal recessive
polycystic kidney disease (ARPKD) renal epithelial cells were
treated with vehicle (control), R-568 (30 and 50 mmol/l), or calcium
(3 and 5mmol/l) for 24 h and cellular proliferation determined.
The results demonstrated that R-568 dose dependently inhibited
cellular proliferation, whereas calcium treatment had no effect in
human ARPKD renal epithelial cells. *Po0.05, versus control and
#Po0.05, R-568 (50mmol/l) versus R-568 (30 mmol/l).
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Histomorphometric analysis
Transverse sections of the kidney, including cortex, medulla, and
papilla, were paraffin processed and sections stained with hematox-
ylin and eosin to measure cyst volume or with picrosirius red stain
to assess fibrosis.30 In a blinded analysis, random regions of the
cortex/outer medulla were photographed and evaluated for cystic
change (cyst volume density, Vv). The amount of cystic change was
determined using point count stereology methods, as previously
described.10,17 Briefly, the percentages of intersects from the grid
that overlie cysts were determined as a percentage of the total grid
intersects that overlie the kidney section, so that cyst Vv was
expressed as a percentage of the kidney section, which was
extrapolated to the percentage of the kidney mass. The total cystic
volume was determined by multiplying the Vv by the kidney weight
to determine the cubic centimeters (ml) of total cyst volume. The
fibrosis score was determined from picrosirius red stain-stained
sections and the percentage of fibrosis evaluated within the
interstitial/intertubular space using a semiquantitative 1þ to 4þ
score: 1þ indicated a minimal amount of fibrosis (o5% if the
intertubular region) and 4þ indicated 460%. This method was
chosen, as the fibrosis was limited to the interstitial, intertubular
regions, and an automated, regional assessment of staining would be
compromised by the amount of cystic pathology, as cysts do not
have fibrosis within their lumina.
In situ hybridization
To confirm localization of the CaSR in cyst epithelial cells, in situ
hybridization was performed on the paraffin sections of the kidneys
from pcy mice, as previously described.32 The specimens were
prehybridized for 2 h at 421C and hybridized with the labeled
riboprobe (5 ng/ml) for 16 h. Riboprobes were made by in vitro
transcription of linearized plasmids (PGEM-T) containing cDNA
for mouse or rat CaSR (kindly provided by Drs Bill Richard and
Charles Henley from Amgen Thousand Oaks, CA). In vitro
transcription was performed in the presence of digoxigenin–
deoxyuridine 50-triphosphate and T7 RNA polymerase (antisense
probe) or Sp6 RNA polymerase (sense probe) according to the
manufacturer’s instruction (Roche Diagnostics, Indianapolis, IN).
Specimens were washed under stringent conditions. After hybridiza-
tion, sections were washed for 30min in 2 SSC at room
temperature and then 1 h each in 1 SSC, 0.5 SSC, and 0.1 SSC
in the presence of 50% formamide at 481C. Probe binding was
localized by a colorimetric reaction with an alkaline phosphatase-
conjugated anti-digoxigenin antibody (Roche Diagnostics). Methyl-
green was used for counterstaining. For negative controls, serial
sections were processed using sense probe.
Content of cAMP in whole kidneys from pcy mice and
immortalized human ARPKD renal epithelial cells
Kidneys were ground to fine powder under liquid nitrogen in a
stainless steel mortar and homogenized in 10 volumes of cold 5%
trichloroacetic acid in a glass–teflon tissue grinder. After centrifuga-
tion at 600 g for 10min, supernatants were extracted with three
volumes of water-saturated ether. After drying the aqueous extracts,
reconstituted samples were processed without acetylation using an
enzyme immunoassay kit (Assay Designs, Plymouth Meeting, PA).
Human-immortalized renal epithelial cells isolated from ARPKD
patients33 were treated with or without R-568 for 24 h. Conditioned
media were collected and cellular lysate isolated. cAMP was
determined using an immunoassay kit (Assay Designs) and
normalized by total cellular protein content.
Intracellular Ca2þ measurement
Isolated human-immortalized renal epithelial cells were treated with
or without R-568 for 1 h. Cells were then loaded with 5 mmol/l fura
4-AM (Molecular Probes, Eugene, OR), a fluro calcium indicator, in
Hank’s balanced saline solution for 30min at 371C. Cells were rinsed
and incubated for an additional 30min with Hank’s balanced saline
solution alone to allow for complete de-esterification of the
fluorescent probe. Intracellular calcium changes were examined by
confocal microscopy and quantified using Metamorph software
(Molecular Device, Sunnyvale, CA), as previously published.34
Cellular proliferation assay
Human-immortalized renal epithelial cells isolated from ARPKD
patients33 were seeded in a 96-well culture plate and treated with
various concentrations of R-568 or CaCl2 for 24 h. Cellular
proliferation was determined by the Promega Cell Titer 96 Aqueous
One Solution Cell Proliferation Assay kit (Promega, Madison, WI)
according to the manufacture’s instructions.
Statistical analysis
Comparisons between groups were made using one-way or two-way
analysis of variance, with least significant difference comparisons
of the means or Student’s t-test as appropriate. Data are expressed
as mean±s.d. Analyses were done using StatView software (SAS,
Cary, NC).
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